Tonix publishes TNX-1500 xenotransplantation workshop presentation

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp.

TNXP

0.00
  • Tonix published a medical research presentation outlining its TNX-1500 anti-CD40L monoclonal antibody program for prevention of kidney transplant rejection, including applications in clinical xenotransplantation.
  • The deck positions TNX-1500 as a third-generation anti-CD40L antibody engineered to reduce platelet-related thrombotic risk by lowering FcγRIIa binding while preserving immunomodulatory activity.
  • Tonix also flagged potential expansion into autoimmune indications, citing examples such as Sjögren’s syndrome, psoriatic arthritis, and multiple sclerosis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on May 17, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.